Account 619-544-3501 | MCC 269-741-1682 | v3.1 Skill-Informed Audit

Brainzyme Google Ads -- Audit & Strategy Dashboard

55 files reviewed | 74-check audit framework | 6 skills loaded | 1 April 2026
F38/100
Account healthUrgent intervention required
Previous: D (50/100) -- revised down after skill audit
Current ROAS
1.36x
Target: 3.5x | May be inaccurate (29 conv. actions)
Current CPA
GBP 31
Target: GBP 20
Hard savings achieved
GBP 5.3k
Per month, already executed
Total improvement est.
GBP 15.7k
Hard saves + projected revenue
Score revised from D (50/100) to F (38/100) after loading ads-google, ads-budget, ads-creative, ads-landing, paid-ads skills plus compliance, google-audit, and benchmarks references. Key additions: Consent Mode v2 gap, missing ad extensions, bidding mismatch, brand exclusion absence.
Category Scores (74-check framework)
Conversion Tracking (25% weight)25/100 -- CRITICAL
Wasted Spend (20% weight)55/100
Account Structure (15% weight)45/100
Keywords & Quality Score (15% weight)30/100 -- FAIL
Ads & Assets (15% weight)35/100 -- FAIL
Settings & Targeting (10% weight)40/100
Budget & Bidding Score
Allocation Strategy60/100
Bidding Strategies40/100
Scaling Readiness45/100
Budget Sufficiency65/100
Detailed Checks -- Conversion Tracking
Detailed Checks -- Ads & Assets
Detailed Checks -- Keywords & QS
What the skills caught that previous reviews missed
GapSource SkillWhy It Matters
Consent Mode v2compliance.mdMandatory for EU/EEA since July 2025. Not in any of 55 files.
Ad extensions absentgoogle-audit G50-53High QS = 50% CPC discount. Low QS = 400% premium.
Bidding mismatchads-budget decision tree<30 conv/month should be Max Clicks, not MaxConvValue.
Brand exclusions in PMaxgoogle-audit G07, G-PM3PMax without exclusions cannibalises brand Search.
Healthcare remarketingcompliance.mdGoogle prohibits remarketing for health services.
MER not calculatedads-budgetBlended Marketing Efficiency Ratio is the true north metric.
Multiple compliance issues found across 4 markets. Some are legal requirements (Consent Mode v2), others are regulatory risks (DGCCRF, HWG, ASA, FTC).
Critical (fix immediately)
!
FR Ritaline in paid ads CRITICAL
UFC-Que Choisir directly named Brainzyme in "Attention aux pilules anti-TDAH". HAS Sept 2024 excludes supplements from ADHD treatment. Files contradict: 09-FR says NEVER, but 13-FR includes Ritaline Alternative PMax asset group (AG3) and 14 includes Search RSA Campaign 6. Remove both. Keep organic/SEO only.
!
Consent Mode v2 (DE + FR) CRITICAL / LEGAL
Mandatory for EU/EEA since July 2025. Not mentioned in any of 55 files. Without it: 90-95% conversion metric drops AND potential GDPR enforcement. Verify implementation on brainzyme.de and brainzyme.fr immediately.
High severity
!
DE "Ohne Nebenwirkungen" HIGH / HWG
"Without side effects" is a medical claim that violates Heilmittelwerbegesetz (HWG). Found in DE PMax AG2 headlines. Replace with "Pflanzlich & Gut Vertraglich" (Plant-Based & Well-Tolerated).
!
FR "Traitement Naturel Fatigue" HIGH / DGCCRF
"Traitement" = "treatment" in French. DGCCRF may consider this a medical claim for a supplement. Change to "solution naturelle" or "soutien naturel".
!
US Elite pricing error HIGH / MISLEADING
Price Extensions in 13-US list Focus Elite at "$29" when it's GBP 47 (~$60+). This would be misleading advertising under FTC guidelines. Fix before deploying.
Medium severity (monitor)
i
UK "#1 Rated" superlative MEDIUM / ASA
Needs ASA-compliant substantiation. If 4.74/5 is genuinely highest in category, document evidence. Otherwise soften to "One of the UK's Highest-Rated".
i
DE ADHS in ad copy MEDIUM / HWG
Strategy bans "ADHD" (English) and "TDAH" (French) but uses "ADHS" (German) freely in headlines. Legal under current HWG interpretation but BfArM has been tightening supplement rules. Monitor.
i
Healthcare remarketing risk UNKNOWN
Google prohibits remarketing for health services. PMax campaigns may be doing this via audience signals. Verify PMax audience configuration.
Compliance pass (good)
These decisions are strategically sound and data-supported. Continue executing.
1
Demand Gen pause DONE Saves GBP 3,476/mo
7 campaigns at 0.21x ROAS. Pure waste. No argument.
2
US reduction DONE Saves GBP 1,636/mo
PMax US Adderall paused (0.01x ROAS, GBP 6,444 CPA). PMax USA halved to GBP 30/day. 40+ historical non-brand US campaigns have never sustained >2x ROAS.
3
DE market -- proceed aggressively BEST OPPORTUNITY
Brainzyme is the ONLY brand running Google Ads on focus/nootropic keywords in Germany. BRAINEFFECT pivoted to gut health. Zero competition window. Ritalin/ADHS Search + Konzentration campaigns should be top priority.
4
FR anti-fatigue mentale pivot WHITE SPACE
52% of French adults report fatigue as #1 complaint. "Anti fatigue mentale" has 500-1,500 monthly searches with near-zero PPC competition. Safer than Ritaline positioning and higher upside.
5
UK problem-aware keyword strategy SMART
Targeting "brain fog help", "can't concentrate" at GBP 0.50-1.50 CPC instead of GBP 3-4 for generic supplement terms. 7 well-segmented ad groups.
6
SERP DE brand CPC increase DONE
Raised from GBP 1.00 to GBP 2.00. At 10.9x ROAS and only 52% impression share, was leaving profitable impressions on the table.
7
Negative keywords on SERP UK ADHD DONE
13 phrase-match negatives for medication/prescription terms. Good call excluding kids/children since FOCUS ORIGINAL works for ages 10-15.
8
70/20/10 budget framework SOUND
UK 45% / DE 41% / FR 14% / US 2%. Follows proven/scaling/testing logic.
These items should be rolled back or not proceeded with. Each has a clear reason.
OK
ROAS guardrails ALREADY ROLLED BACK
200% Target ROAS on campaigns with 24-month-old creative forced Smart Bidding into a death spiral. PMax FR dropped from 1.49x to 0.86x within days. Correct sequence: creative refresh FIRST, then guardrails. The rollback was the right call.
X
FR Ritaline paid ads DO NOT PROCEED
Files 09-FR and 13-FR directly contradict each other. UFC-Que Choisir named Brainzyme. HAS Sept 2024 guidelines exclude supplements from ADHD treatment. Remove AG3 from FR PMax plan. Hold Campaign 6 from Search RSA plan. Keep organic/SEO presence only.
X
DE "Ohne Nebenwirkungen" headline REMOVE
HWG violation. "Without side effects" is a medical claim. Replace with "Pflanzlich & Gut Vertraglich" (Plant-Based & Well-Tolerated).
X
US Elite pricing in ad copy FIX
Price Extensions list Focus Elite at "$29" when it's GBP 47 (~$60+). Misleading advertising under FTC guidelines.
!
Creative brief Image 8 "beaker" REVISE
File 10 specifies "beaker, clinical aesthetic" but brand exclusion rules explicitly ban beakers. Replace with peer-reviewed journal or ingredient close-up on marble.
These are hard blockers that must be resolved before new campaigns launch or creative deploys.
Hard Blockers
1
Audit all 29 conversion actions HARD BLOCKER
Reduce to Purchase-only as Primary. With 29 polluted actions, every Smart Bidding decision is compromised. The ROAS figures themselves may not be accurate. Nothing else should proceed until this is done.
2
Verify Consent Mode v2 (DE + FR) LEGAL REQUIREMENT
Mandatory for EU/EEA since July 2025. If not implemented: 90-95% of conversion data from EU traffic is lost AND potential GDPR enforcement risk.
3
Live-verify all 64 landing page URLs 5-MINUTE FIX
File 11 URLs from Google Docs extraction, not live crawling. File 05-UK found 6/9 guessed URLs returning 404. Batch crawl before any campaign goes live.
Quick Wins (unblock immediately)
4
Connect DE product feed USER ACTION
Two proven campaigns (2.43x and 2.04x ROAS) sitting at GBP 0.01/day because product feed isn't connected. Easiest revenue recovery in the account.
5
Add RSA to Focus & Attention ad group COPY READY
Ad group created with 10 keywords but no RSA ad. Keywords without ads don't serve. Copy exists in file 04.
6
Add ad extensions to ALL Search campaigns NEW FINDING
Sitelinks, callouts, structured snippets, image extensions -- entirely missing from all 55 files. Per benchmarks: high QS from extensions = 50% CPC discount. Low QS = 400% premium.
7
Remove compliance violations from ad copy BEFORE DEPLOY
"Ohne Nebenwirkungen" (DE), "Traitement" (FR), US Elite pricing ($29). All must be fixed before any new copy goes live.
Campaign creation note
i
API campaign creation is broken WORKAROUND
create_campaign MCP tool failed 5 different ways (documented as T5). All 5 new Search campaigns must be created manually in Google Ads UI. Deployment specs in file 05 are UI-ready with every setting specified.
This is the corrected priority sequence. The original v1 strategy had the right items but wrong order. Skills revealed that infrastructure (conversion tracking, consent mode, extensions) must come before strategy execution.
Week 1: Foundation (Hard Blockers)BEFORE ANYTHING ELSE
1. Audit all 29 conversion actions
Reduce to Purchase-only as Primary. This is the foundation everything else builds on. Without it, all ROAS figures are unreliable and Smart Bidding is flying blind.
2. Verify Consent Mode v2 (DE + FR)
Mandatory for EU/EEA since July 2025. Without it, 90-95% of conversion data from EU traffic is lost. Check brainzyme.de and brainzyme.fr implementations.
3. Live-verify all 64 landing page URLs
5-minute batch crawl. Prevents sending paid traffic to 404 pages. Previous round found 6/9 guessed URLs returning 404.
Week 2: Quick WinsHIGH ROI, LOW EFFORT
4. Connect DE product feed
Unblocks 2.43x ROAS PMax DE Ritalin + 2.04x PMax DE Austria Ritalin. Easiest revenue recovery in the account. Requires Shopify/Google Merchant Center action.
5. Add RSA to Focus & Attention ad group
Copy written in file 04. Keywords exist but no ad serves without RSA.
6. Add ad extensions to ALL Search campaigns
Sitelinks (4+), callouts (4+), structured snippets, image extensions. Entirely missing. Direct QS and Ad Rank impact.
7. Fix compliance issues in ad copy
Remove "Ohne Nebenwirkungen" (DE HWG), change "Traitement" to "Solution" (FR DGCCRF), fix US Elite pricing ($29 -> correct price).
Week 3-4: Creative RefreshBIGGEST PERFORMANCE LEVER
8. PMax creative refresh (all markets)
24-month-old UK assets are the #1 performance drag after conversion tracking. UK ROAS collapsed from 3.53x to 1.44x with zero refresh. Per benchmarks, refresh every 8-12 weeks.
9. Deploy new Search campaigns via UI
5 campaigns with full specs in file 05. API creation broken (T5). Create PAUSED, verify settings, then enable.
Week 5+: Guardrails & ScalingAFTER BASELINES ESTABLISHED
10. Re-apply ROAS guardrails
ONLY after creative refresh has had 2+ weeks to establish new baselines. Previous attempt without fresh creative caused PMax FR to drop from 1.49x to 0.86x.
11. Launch FR anti-fatigue mentale + DE Konzentration
New Search campaigns targeting white-space keywords. FR: zero PPC competition on anti-fatigue. DE: zero competitor Google Ads presence.
12. Scale DE aggressively
Once Ritalin/ADHS Search + Konzentration campaigns are live and converting, increase DE budget allocation. Zero competition window won't last forever.
Budget Allocation
UK
45%
GBP 9,180/mo | Proven
DE
41%
GBP 8,364/mo | Scaling
FR
14%
GBP 2,856/mo | Scaling
US
2%
GBP 360/mo | Defence
UK -- Problem-Based Focus
"Can't concentrate? There's a plant-powered solution."
Strategy: Target problem-aware keywords at GBP 0.50-1.50 CPC (vs GBP 3-4 generics)
Campaigns: Brand Search (9.01x ROAS), Problem-Aware Search (new), PMax UK (refresh)
Strengths: 6,020+ reviews, 2,000+ doctors, 365-day returns, Made in Scotland
Key keywords: brain fog help, can't concentrate, focus supplements, mental fatigue
Note: Brain Quiz does NOT convert for paid traffic. SERP UK ADHD QS catastrophe (16/19 at QS 0-3).
DE -- Ritalin Alternative + Konzentration (BIGGEST OPPORTUNITY)
"Konzentration naturlich steigern"
Strategy: Exploit zero-competition window. Only brand bidding in Germany.
Campaigns: Brand Search (10.9x ROAS), Ritalin/ADHS Search (new), Konzentration Search (new), PMax DE (refresh)
Unique: BRAINEFFECT pivoted to gut health. No German domestic brand bidding.
Blockers: Product feed not connected (blocks PMax DE Ritalin at 2.43x ROAS)
Watch: ADHS in ad copy (HWG risk). "Ohne Nebenwirkungen" must be removed.
FR -- Anti-Fatigue Mentale (White Space)
"Anti-fatigue mentale -- concentration naturelle"
Strategy: Dual-track: shift from Ritaline (60% now -> 20% by M6) to anti-fatigue mentale (40% -> 80%)
Campaigns: Brand Search (16.5x ROAS), Anti-Fatigue Mentale Search (new), PMax FR (refresh)
Opportunity: 52% of French adults report fatigue as #1 complaint. EUR 250m pharmacy market. Zero PPC competition.
CRITICAL: Do NOT run paid Ritaline ads. UFC-Que Choisir named Brainzyme. Fix "Traitement" language.
US -- Brand Defence Only (Survival Mode)
Minimal spend. Brand search only. No expansion.
Strategy: GBP 30/day brand search only. 40+ historical non-brand campaigns never sustained >2x ROAS.
Issues: All pages show same H1, zero reviews visible. SERP USA Brand has 0 conversions (likely broken tag).
Rule: Scale only if ROAS sustains >1.5x for 3+ months.
Fix US Elite pricing ($29 shown, actual ~$60). Verify conversion tag on US store checkout.
Hard savings (already executed)
GBP 5,298/mo
Demand Gen pause + US reduction + negatives
Projected revenue gains
GBP 10,464/mo
Depends on creative refresh + DE reactivation
ActionTypeStatusMonthly Impact
Pause Demand Gen (7 campaigns)Hard saveDONE+GBP 3,414
PMax US Adderall pause + USA budget cutHard saveDONE+GBP 1,636
ADHD negative keywordsHard saveDONE+GBP 248
Re-enable PMax DE RitalinRevenue est.BLOCKED+GBP 2,700
US budget reallocation to DEReallocationPENDING+GBP 1,900
PMax creative refresh (all markets)Revenue est.WEEK 3-4+GBP 5,864
Total+GBP 15,762/mo
Important caveat: Hard savings (GBP 5,298/mo) are real and already achieved. The remaining GBP 10,464/mo depends on creative refresh restoring historical ROAS levels and DE product feed being connected. Plausible but not guaranteed.
Image generation costs (already incurred)
SessionImagesModelsCost
Session 1 (31 Mar)20Flux Kontext Max, Nano Banana Pro~GBP 2.06
Session 2 (1 Apr)42Flux Kontext Max, Nano Banana Pro, Ideogram v3~GBP 3.16
Total62~GBP 5.22
Interactive projections using google-ads-math formulas. Drag sliders to model different scenarios. All calculations use 30.4 days/month. Inputs are pre-filled with current account data.

Creative Refresh Impact Projector

Model what happens to revenue when PMax ROAS recovers after refreshing 24-month-old creative. Based on historical ROAS trajectory.
2.0x
2.0x
1.8x
GBP 1,555
GBP 2,712
GBP 1,177
Current monthly revenue
GBP 32,140
Projected monthly revenue
GBP 45,390
Monthly revenue uplift
+GBP 13,250
Formula: Monthly Revenue = Weekly Spend x 4.34 x ROAS. Current ROAS: UK 1.44x, DE 1.36x, FR 1.49x. Historical peak: UK 3.53x (Jan 2025).

Impression Share Opportunity

What revenue is being left on the table from lost impression share?
80%
50%
12.0%
6.0%
GBP 35
DE Brand: current 52.1% IS--
UK ADHD: current 14.7% IS--
Est. missed clicks/month (DE)--
Est. missed conversions/month (DE)--
Est. missed revenue/month (total)--
Formula: Missed Impr = Current Impr x ((1 - IS) / IS). Missed Clicks = Missed Impr x CTR. Missed Conv = Missed Clicks x CVR. Missed Rev = Missed Conv x AOV.

Break-Even ROAS Calculator

What ROAS do you need to break even given your margin?
50%
GBP 20,000
2.1x
Break-even ROAS--
Current revenue/month--
Current gross profit/month--
Net profit after ad spend--
Verdict--
Formula: Break-Even ROAS = 1 / Margin. Net Profit = (Revenue x Margin) - Ad Spend. At 50% margin, you need 2.0x ROAS to break even.

Budget Projection Calculator

Model monthly output from daily budget, CPC, and conversion rate.
GBP 100
GBP 1.20
3.5%
GBP 35
Daily clicks--
Daily conversions--
Monthly spend--
Monthly conversions--
Monthly CPA--
Monthly revenue--
Projected ROAS--
Formula: Daily Clicks = Budget / CPC. Daily Conv = Clicks x CVR. Monthly = x 30.4. ROAS = Revenue / Spend.

Germany Scaling Projector

Model the impact of scaling DE -- zero competition window. Uses 20% scaling rule.
GBP 50
GBP 30
GBP 14.84
GBP 22
GBP 36
DE Ritalin: monthly conversions--
DE Ritalin: monthly revenue--
DE Konzentration: monthly conversions--
DE Konzentration: monthly revenue--
Combined DE new monthly spend--
Combined DE new monthly revenue--
Blended DE ROAS--
DE Ritalin CPA based on lifetime 2,468 conversions at GBP 14.84. Konzentration CPA estimated -- new campaign, no competitors. 20% rule: scale budget by max 20% every 5 days once CPA stabilises.

CPA Sensitivity Analysis

How does CPA change when CPC or CVR shifts? Drag to model market conditions.
GBP 1.50
0%
3.5%
0%
Base CPA--
Adjusted CPC--
Adjusted CVR--
New CPA--
CPA change--
Formula: CPA = CPC / CVR. A 20% CPC increase with flat CVR = 20% CPA increase. A 20% CVR improvement with flat CPC = 17% CPA decrease. QS improvements reduce CPC: each QS point = ~10-15% CPC reduction.

12-Month Revenue Forecast

Month-by-month projected revenue based on implementation timeline. Assumes phased improvements from the priority sequence.
GBP 20,000
2.5x
4 months
Year 1 ad spend
--
Year 1 projected revenue
--
Year 1 blended ROAS
--
Assumes: Month 1 at current 1.36x ROAS (fixing conversion tracking). Months 2-3 creative refresh deployed. Linear ROAS ramp to target over specified months. Steady state thereafter. Spend held constant -- no 20% scaling rule applied here for simplicity.

Budget Reallocation Modeller

Drag market allocation to see total revenue impact. Based on current per-market ROAS (conservative) or projected post-refresh ROAS.
45%
41%
12%
2%
GBP 20,000
Total monthly revenue
--
Blended ROAS
--
vs. current revenue
--
UK: spend / revenue--
DE: spend / revenue--
FR: spend / revenue--
US: spend / revenue--
Current ROAS: UK 1.44x, DE 1.36x (blended w/ brand 3.8x), FR 1.49x, US 0.95x. Post-refresh projections: UK 2.2x, DE 2.5x (incl. Ritalin reactivation), FR 2.0x, US 1.2x. Brand search ROAS included in blended figures.
Executed changes (verified)
#DateChangeStatusImpact
131 MarPaused 7 Demand Gen campaignsDONEGBP 3,476/mo saved
231 MarEnabled PMax DE Ritalin (GBP 0.01/day)BLOCKEDNeeds product feed
331 MarEnabled PMax DE Austria Ritalin (GBP 0.01/day)BLOCKEDNeeds product feed
431 MarAdded 13 negative keywords to SERP UK ADHDDONEGBP 248/mo saved
531 MarUS Brand Search reverted to Target Impression ShareDONE (user)Restores GBP 2.47 CPA
61 AprPaused PMax US Adderall TestDONEGBP 136/mo saved
71 AprReduced PMax USA budget to GBP 30/dayDONEGBP 1,500/mo saved
8-101 AprApplied 200% ROAS guardrails (UK/DE/FR PMax)ROLLED BACKFR dropped to 0.86x
111 AprRaised SERP DE brand CPC ceiling to GBP 2.00DONECaptures ~48% more brand traffic
121 AprCreated Focus & Attention ad group (10 keywords)PARTIALNo RSA ad yet
13-151 AprRolled back all ROAS guardrailsCORRECTCreative first, then guardrails
Technical issues encountered
IDIssueSeverityWorkaround
T1switch_bidding_strategy fails on PMaxMediumUse generic_mutate with explicit field path
T2generate_keyword_ideas blocked (Explorer token)MediumUse search terms, web research, UI Planner
T5create_campaign completely broken (5 failure modes)HighAll campaigns via Google Ads UI
T6Flux Kontext Max rejects 4:5 aspect ratioLowUse 3:4 instead
MCP tool reliability (29 tools tested)
Reliable
19
Partial
3
Broken
1
Blocked
1
Untested
1
Loading...